Technical Analysis for BNOX - Bionomics Limited

Grade Last Price % Change Price Change
C 12.01 -3.84% -0.48
BNOX closed down 3.84 percent on Thursday, January 20, 2022, on 48 percent of normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Flat
Historical BNOX trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Hot IPO Pullback Bullish Swing Setup 0.00%
Inside Day Range Contraction 0.00%
20 DMA Support Bullish -3.84%
Stochastic Reached Overbought Strength -3.84%
Overbought Stochastic Strength -3.84%
Narrow Range Bar Range Contraction -5.13%
Shooting Star Candlestick Bearish -3.30%
Narrow Range Bar Range Contraction -3.30%
Doji - Bearish? Reversal -3.30%
Older End-of-Day Signals for BNOX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Bionomics Limited Description

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Medicine Drugs Cancer Treatment Stem Cell Monoclonal Antibodies Alzheimer's Disease Antineoplastic Drugs Central Nervous System Disorders Treatment Of Central Nervous System Disorders Camidanlumab Tesirine Post Traumatic Stress Disorder Anxiolytics Cognitive Impairment Milatuzumab

Is BNOX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 22.0
52 Week Low 10.53
Average Volume 15,113
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 12.28
10-Day Moving Average 12.03
Average True Range 1.17
ADX 0.0
+DI 9.92
-DI 13.54
Chandelier Exit (Long, 3 ATRs) 18.48
Chandelier Exit (Short, 3 ATRs) 14.05
Upper Bollinger Bands 13.08
Lower Bollinger Band 11.49
Percent B (%b) 0.33
BandWidth 12.91
MACD Line -0.16
MACD Signal Line -0.17
MACD Histogram 0.0103
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.26
Resistance 3 (R3) 13.38 13.08 13.05
Resistance 2 (R2) 13.08 12.76 13.02 12.98
Resistance 1 (R1) 12.55 12.57 12.40 12.43 12.91
Pivot Point 12.25 12.25 12.17 12.19 12.25
Support 1 (S1) 11.71 11.93 11.56 11.59 11.11
Support 2 (S2) 11.41 11.73 11.35 11.04
Support 3 (S3) 10.88 11.41 10.97
Support 4 (S4) 10.76